High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients

[1]  K. Jang,et al.  Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. , 2020, ESMO open.

[2]  P. Ascierto,et al.  Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[3]  P. Dundr,et al.  A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants , 2019, Scientific Reports.

[4]  M. Denis,et al.  Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay , 2019, PloS one.

[5]  E. Raso,et al.  Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma , 2019, BMC Cancer.

[6]  J. Eshleman,et al.  Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing , 2019, BMC Cancer.

[7]  G. Orchard,et al.  Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma , 2019, British journal of biomedical science.

[8]  P. Ulivi,et al.  Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? , 2018, International journal of molecular sciences.

[9]  L. Carvalho,et al.  Heterogeneity in Lung Cancer , 2018, Pathobiology.

[10]  S. Mocellin,et al.  BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors , 2018, Molecular Cancer Therapeutics.

[11]  G. Turashvili,et al.  Tumor Heterogeneity in Breast Cancer , 2017, Front. Med..

[12]  Liang Cheng,et al.  Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine , 2017, Modern Pathology.

[13]  G. McArthur,et al.  Tumour mutation status and sites of metastasis in patients with cutaneous melanoma , 2017, British Journal of Cancer.

[14]  E. Amir,et al.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer , 2017, British Journal of Cancer.

[15]  C. Berking,et al.  Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care , 2017, BMC Cancer.

[16]  M. Millward,et al.  Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma , 2017, Pigment cell & melanoma research.

[17]  J. Wilmott,et al.  BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting , 2016, Histopathology.

[18]  J. Garioch,et al.  A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma , 2016, British Journal of Cancer.

[19]  L. Akslen,et al.  BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival , 2016, British Journal of Cancer.

[20]  C. Berking,et al.  Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma , 2015, Oncotarget.

[21]  Alison White,et al.  FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor , 2015, Pathology.

[22]  J. Mosser,et al.  Prognostic and predictive values of oncogenic BRAF, NRAS, c‐KIT and MITF in cutaneous and mucous melanoma , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  J. Emile,et al.  Variations of BRAF mutant allele percentage in melanomas , 2015, BMC Cancer.

[24]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[25]  Soo-Nyung Kim,et al.  Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. , 2015, Journal of the American Academy of Dermatology.

[26]  Parisha Bhatia,et al.  Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. , 2015, Annals of translational medicine.

[27]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[28]  R. Porcher,et al.  BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma. , 2014, Melanoma research.

[29]  A. Eggermont,et al.  Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site , 2014, Annals of Surgical Oncology.

[30]  Jacqueline A. L. MacArthur,et al.  Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants , 2013, Nucleic Acids Res..

[31]  L. Heinzerling,et al.  Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations , 2013, British Journal of Cancer.

[32]  H. Kaufman,et al.  Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions , 2013, American Journal of Clinical Dermatology.

[33]  M. Mazumdar,et al.  Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma , 2012, PloS one.

[34]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[35]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[36]  R. Scolyer,et al.  BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.

[37]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[38]  C. Petti,et al.  In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation , 2008, Modern Pathology.

[39]  R. Millikan,et al.  Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[40]  J. Lundeberg,et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.

[41]  G. Saldanha,et al.  Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies , 2006, Clinical Cancer Research.

[42]  J. McCubrey,et al.  Detection of BRAF gene mutation in primary choroidal melanoma tissue , 2006, Cancer biology & therapy.

[43]  L. Kanter,et al.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[45]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.